Prostate cancer ‘Rosetta stone’ paves way to targeted drugs

Genetic study could provide hope for men with advanced forms of the disease with findings that could lead to personalised treatments

A genetic study described by researchers as the Rosetta stone of prostate cancer could provide hope for men with advanced forms of the disease.

British and US scientists who drew up the first comprehensive map of genetic mutations linked to different strains of prostate cancer found that almost 90% of the men whose DNA they studied carried potentially treatable defects.